Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MOGAT2 | Q3SYC2 | 4/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30280390 | 0.93 | PTPN11 (0.42) | PTPN11ESR2MOGAT2PREPHTR6 | |
| SCHEMBL31396505 | 0.88 | PTPN11 (0.43) | PTPN11CYP2D6MEN1KMT2AMOGAT2 | |
| SCHEMBL30280414 | 0.84 | PTPN11 (0.43) | PTPN11CYP2D6HTR6CD274CHEK2 | |
| SCHEMBL30280401 | 0.81 | PTPN11 (0.45) | PTPN11CYP2D6MEN1KMT2AHTR6 | |
| SCHEMBL30280405 | 0.81 | ESR2 (0.44) | PTPN11ESR2MEN1KMT2AHTR6 | |
| SCHEMBL25153562 | 0.78 | CHEK1 (0.39) | ESR2KMT2A | |
| SCHEMBL12067531 | 0.78 | PTPN11 (0.45) | PTPN11MEN1KMT2AGPR119TP53 | |
| SCHEMBL31396521 | 0.78 | PTPN11 (0.50) | PTPN11HTR6 | |
| SCHEMBL22324681 | 0.76 | PTPN11 (0.47) | PTPN11MEN1KMT2AGPR119TP53 | |
| SCHEMBL12068204 | 0.76 | PTPN11 (0.42) | PTPN11GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425499-A1 | TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425499-A1 | TYRO3 INHIBITORS | TYRO3, TYR, TH | PTPN11 80/4885CYP2D6 1813/4885ESR2 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.